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Abstract
Stroke is a leading cause of disability and death in many countries. Understanding the
pathophysiology of ischemic injury and developing therapies is an important endeavor that requires
much additional research. Animal stroke models provide an important mechanism for these
activities. A large number of stroke models have been developed and are currently used in
laboratories around the world. These models are overviewed as are approaches for measuring
infarct size and functional outcome.
Utility of Animal Models of Ischemic Stroke
Stroke is the third leading cause of death and a major
cause of disability in the United States [1,2]. Each year,
there are approximately 731,000 new strokes and half of
the survivors suffer from permanent handicap [3]. Stroke
costs the United States approximately $50 billion annu-
ally in direct and indirect costs [4]. Given these facts,
stroke is a major public health issue requiring urgent
development of effective therapies: experimental models
of focal brain ischemia help in achieving this goal.
80% of human strokes are ischemic in origin [2]. Thus,
experimental models of focal cerebral ischemia have been
developed in an attempt to closely mimic the changes that
occur during and after human ischemic stroke. These
models are used to discover the mechanisms involved in
the evolution of ischemic injury which, in turn, can lead
to the development of novel therapeutic strategies for
stroke. These same animal models can then be used to test
the safety and efficacy of these treatments in vivo.
Most human ischemic strokes are caused by occlusion of
the middle cerebral artery (MCA) [5] and so animal mod-
els were developed to induce ischemia in this arterial ter-
ritory. These models aim to satisfy the following criteria:
(1) to mimic the pathophysiological changes found in
human stroke, (2) to create reproducible lesions, (3) to
employ procedures that are relatively simple and nonin-
vasive, (4) to be of low financial cost, and (5) to enable
monitoring of physiologic parameters and analysis of
brain tissue for outcome measures [6].
Many higher animal species fulfill the aforementioned
stroke modeling criteria; however, rats are the most com-
monly used animals for several reasons, including: (1)
their resemblance to humans in their cerebral anatomy
and physiology, (2) their small size which enables easy
analysis of physiology and brain tissue, (3) their low cost,
(4) the remarkable genetic homogeneity within strains,
and (5) greater public and institutional ethical acceptabil-
ity of use relative to larger animals. Thus, the remainder of
this chapter will focus primarily on rat models of ischemic
stroke [7-9].
Permanent versus Transient Ischemia
Focal brain ischemia models can be categorized into two
groups: permanent and transient ischemia. Permanent
ischemia results in a region of severe ischemic damage
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(core) surrounded by a zone of less damaged tissue [10].
Reestablishment of perfusion after 3 hours does not
reduce infarct size in all animal models [11].
Transient focal ischemia produces varying degrees of
ischemic damage depending on the duration of ischemia.
In rats, as little as 8 minutes of ischemia causes selective
neural necrosis and ischemia for more than 30 minutes is
always associated with infarction [12]. Importantly, after
transient ischemia, brain damage results from both the
ischemia and the effects of reperfusion (reperfusion
injury). Compared to permanent occlusion, which mimic
only a minority of human strokes where there is no reca-
nalization, transient models better correlate with condi-
tions such as therapy-induced thrombolysis, spontaneous
thrombolysis, and transient ischemic attack. However,
both permanent and transient ischemia models are
needed prior to clinical drug development studies because
of the heterogeneity of human stroke [13,14].
Long-term studies are becoming increasingly important in
translational stroke research; thus, the animal survival rate
should be considered when designing an experimental
protocol. Generally, regardless of the employed tech-
nique, models of transient ischemia offer higher survival
rates relative to permanent occlusion and thus may be
more suited for long-term studies. Additionally, survival is
enhanced by proper surgical technique, maintaining
physiological parameters within normal ranges during
experimentation, and attention to animal nutrition,
among other things. For studies of neuroprotection and/
or thrombolysis, the effects of putative therapies on sur-
vivability must also be taken into consideration.
Rat Models of Focal Cerebral Ischemia
Many animal models of focal cerebral ischemia exist. In
this chapter, special focus is paid to the intraluminal MCA
occlusion and embolus models because of their relatively
widespread use in the development of treatments for
stroke. Importantly, these methods can also be performed
on mice, allowing for transgenic studies of the pathophys-
iology of stroke.
Intraluminal MCA Occlusion Model
This model was originally described by Koizumi et al and
has since been modified by others [11]. It is the most com-
monly used of rat models of stroke due to its relative sim-
plicity and noninvasiveness. The MCA is occluded by
inserting a monofilament suture into the internal carotid
artery (ICA) to block blood flow to the MCA either perma-
nently or transiently by keeping the filament in place or
withdrawing it, respectively. Several manuscripts describe
in detail the technical and procedural features of this
model [11-16].
This model typically induces infarcts in the lateral caudat-
oputamen and frontoparietal cortex [17]. The infarct is
reproducible and there is a significant ischemic penumbra
early after MCA occlusion, making this model suitable for
testing neuroprotective agents [18]. However, several
technical factors may influence infarct size, such as: 1)
physical differences in the employed monofilament
suture, (2) insertion distance of the suture, and (3) acci-
dental premature reperfusion [19-21]. It is therefore
essential that standardized surgical and technical proce-
dures be used by adequately trained personnel in order to
generate reproducible lesions. There are also some com-
plications with the intraluminal MCA occlusion model
such as subarachnoid hemorrhage secondary to suture-
induced arterial rupture, spontaneous hyperthermia when
the duration of ischemia is longer than 2 h, and mechan-
ical damage of endothelium which can complicate reper-
fusion [13,22,23]. The complication rates may be reduced
by using silicone coated sutures [13].
The intraluminal MCAO model is suitable for neuropro-
tection drug experiments because it produces a substantial
amount of penumbra (salvageable tissue) in the first 60-
90 minutes after onset [16]. Also, the location, volume,
and temporal evolution of infarction are similar to those
produced by proximal electrocoagulation of the MCA
[16]. The suture is easily withdrawn, enabling investiga-
tors to study the aspects of reperfusion
The suture MCA occlusion model has recently been mod-
ified to induce ischemia in a magnetic resonance imaging
(MRI) unit by remotely advancing the suture occluder
[16]. This in-bore occlusion method has achieved a high
reproducibility rate and enables investigators to monitor
in vivo ischemic changes at pre-occlusion, acute, subacute
and chronic post-occlusion time points [16]. Combined
with multiparametric MRI techniques, the MCA occlusion
model enables anatomic, diffusion, perfusion, and func-
tional data to be obtained longitudinally and noninva-
sively in the same animal, making it a powerful tool for
studying the pathophysiology of brain ischemia [23,24].
Thromboembolic Model
Though thromboembolic ischemia can be induced by a
photochemical approach, the most commonly used
thromboembolic model is blood clot injection, first
described in the dog by Hill et al. and later applied to the
rat [25-27]. This model is of great interest to researchers
because of its close resemblance to human ischemic
stroke and its utility in evaluating thrombolytic therapies
[28]. Thrombolytic therapy with recombinant tissue plas-
minogen activator (rt-PA) administered intravenously
within 3 h of onset of ischemic stroke in select patients is
the only FDA-approved treatment for human stroke and
has been shown to improve neurological outcome [29].
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Recently, there has been heightened interest in studying
the efficacy of combining thrombolytic and neuroprotec-
tive agents in the treatment of stroke, giving thromboem-
bolic animal models an increasingly important role in this
respect [30].
Several disadvantages were common to the early throm-
boembolic models, such as diffuse and inhomogenous
infarction in the MCA territory from microembolization
to peripheral branches [27]. Additionally, spontaneous
recanalization frequently occurred, making it difficult to
study thrombolytic therapies [16]. Infarct sizes were vari-
able, contralateral strokes were common, and ischemia
caused by multiple small clots did not mimic typical clin-
ical ischemic stroke [16]. Later, it was determined that size
(length and diameter) and the biological characteristics of
the blood clot (fibrin-rich) are crucial to the relevance and
reproducibility of this model [16].
Busch et al developed a rat clot model that surmounted
the above issues in which a single fibrin-rich autologous
clot was injected to produce reliable occlusion of the prox-
imal MCA, with consistent reduction of cerebral blood
flow (CBF) and histological damage in the MCA territory
seen [31]. No spontaneous thrombolysis was observed
and, in separate experiments, thrombolytic therapy with
rt-PA or prourokinase recanalized the occluded MCA
[31,32]. Recently, Henninger et al used the embolic model
in conjunction with multimodal MRI to investigate the
pathophysiological mechanisms underlying the relatively
rare clinical phenomenon of "spectacular shrinking defi-
cit" in stroke patients [33].
In conclusion, the single fibrin-rich clot model induces
reproducible infarcts in the MCA territory similar to those
produced by the intraluminal MCA occlusion model. The
clot model has the added advantages of bearing closer
similarity to the mechanism underlying human ischemic
stroke and better utility for studying thrombolytic ther-
apy. Combined with modern imaging techniques, throm-
boembolic models have the potential to take the
experimental study of stroke to new frontiers.
Non-clot Embolus Models
Numerous compounds have been used to produce artifi-
cial emboli which are typically injected into the ICA, most
commonly in rats [34]. Microsphere embolization is the
most widely used model, with the severity of ischemic
damage related to the number of emboli used [35]. The
lesions require longer time to develop (24 hours on aver-
age) than in the intraluminal models, allowing for a larger
therapeutic window for drug testing in microsphere mod-
els. However, the permanency of the ischemia does not
simulate most clinical situations which limits the applica-
bility of these models. Also, lesions are multifocal and
have low reproducibility, though recent macrosphere
models have resulted in more reproducible infarcts by
increasing the diameter of the spheres and using less of
them [36].
Direct Surgical MCAO
Numerous techniques have been developed to surgically
approach and occlude the MCA, with the rat being the
species most widely used [13]. The orbital route is the
least traumatic and, compared to procedures requiring
craniotomy, results in less blood loss and artifacts [37].
Electrocautarization of the MCA results in permanent
occlusion, whereas clipping or ligature snares enable
reperfusion [38]. Occlusion of the MCA following a tran-
sient hypotension produces a larger infarct area [39]. Tan-
dem occlusion of the distal MCA and ipsilateral CCA
results in more reproducible infarcts [40]. Recently, a
three-vessel occlusion model has been shown to produce
reproducible and selective neocortical infarction [41].
Common to all of these variants, the procedure is always
invasive and requires extreme surgical skill which limits
their utility.
Photochemically Induced Thrombosis
This model induces a cortical infarct by systemic injection
of a photoactive dye in combination with irradiation by a
light beam transmitted through the intact skull [42]. Oxi-
dative damage to the endothelium caused by the altered
dye leads to platelet aggregation in the irradiated area
[43]. This model is used primarily in spontaneously
hypertensive rats [44]. A disadvantage of this model is that
vasogenic edema and blood-brain barrier breakdown
occur within minutes which does not allow for the forma-
tion of penumbra--therefore, this model has been consid-
ered by many to be unsuitable for preclinical drug studies
[44]. However, a new model overcomes this limitation
and induces ischemia over a greatly extended time period,
consistently producing a penumbra-like region [45]. This,
combined with the ability to noninvasively and reproduc-
ibly induce infarct in any cortical location, are obvious
advantages of the photochemical infarct model. A major
disadvantage is the atypical features of the lesion (promi-
nent vascular injury and early vasogenic edema) which are
unlike human stroke [13].
Endothelin-induced MCAO
Endothelin-1 (ET-1) is a natural peptide that causes vaso-
constriction and several models use this as an agent to
induce MCA stroke [13]. Invasive approaches have been
largely replaced by stereotactic intracerebral injection of
ET-1 adjacent to the MCA, which avoid complications of
surgery [46]. When ET-1 is applied to the MCA there is a
significant decrease of cerebral blood flow (CBF) in its ter-
ritory, resulting in an ischemic lesion pattern similar to
that of direct surgical MCAO [47]. This model may be use-
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ful in restorative drug studies. Notably, after a period (~20
minutes) of severe CBF reduction, there is a slow and pro-
gressive return of blood flow to normal with the rate being
dose-dependent [47]. This can be disadvantageous source
of variability unless the dose is carefully standardized in
the experiment.
Outcome Measures
There are several ways of measuring the severity of
ischemic insult in animals: assessment of neurological sta-
tus, pathological assessment, and in-vivo evaluation with
magnetic resonance imaging (MRI). Most prior studies of
MCAO focus on the acute phase of ischemia but since
neuronal damage can occur days to weeks after insult, it is
reasonable that new studies include evaluation of out-
come measures both in the acute phase (1-3 days) and
chronically (up to 4 weeks) [48].
Assessment of Neurological Status
Many neurological deficits are difficult to assess in ani-
mals. Motor deficits are perhaps the easiest to quantify
and simple measures of motor function are available in
rodent models [49]. Refined tests that assess sensorimotor
function include limb placing, beam walking, sticky label
test, grid walking, and rotarod [50]. A number of cognitive
tests examining learning and short term memory are avail-
able for rats, including the Morris water maze [51]. Com-
bining neurological assessment with histological
measurements is becoming more critical with the height-
ened interest in neuroprotective drugs, the effectiveness of
which may be reflected more by subtle structural and
chemical changes rather than changes in gross infarct vol-
ume [52]. This statement is supported by the fact that ani-
mal data suggest a poor correlation between reductions in
infarct size with neurological or behavioral deficits [13].
Also of importance is the need to extend the period of test-
ing of neurological status for at least 1 month post-insult
in animal studies, per the recommendations of the STAIR
Committee [14]. However, this may be difficult to imple-
ment as survival times are 48 hours or less in many animal
stroke models [53].
Pathological Assessment
In models of focal ischemia, the chief outcome has been
the infarct volume, traditionally measured by quantitative
histology. Among a number of histopathological meth-
ods, 2,3,5-triphenyltetrazolium chloride (TTC) and
hematoxylin-eosin (H&E) staining are the two most com-
monly employed. TTC can be used to stain tissue much
more rapidly, easily, and cheaply than H&E [54]. TTC is a
colorless chemical that is reduced by mitochondrial
enzymes into a compound that stains intact brain regions
dark red whereas infarcted regions remain white. Studies
show TTC staining to be reliable between 6 and 72 hours
post-ischemia [13]. Prior to 6 hours, there may not be suf-
ficient number of damaged mitochondria to create con-
trast between normal and infarcted tissue, and after 72
hours pathophysiologic inflammatory response often
obscures the line of demarcation in the periphery of the
damaged area [13].
Notwithstanding staining techniques, infarcts have com-
plex shapes with sometimes indistinct margins, making it
difficult to measure their volumes. Many methods have
been developed to deal with these complexities, each with
their own advantages and disadvantages. Perhaps one of
the most important considerations to account for is the
effect of vasogenic edema on infarct volume. Edema in the
rat MCAO stroke model typically accounts for 20-30% of
the total apparent infarct volume [55]. Separate measure-
ment of "corrected" infarct volume (which accounts for
edema) and "uncorrected" volume (which does not
account for edema) is important because of the possibility
that some interventions may reduce edema but not sal-
vage brain tissue and vice-versa [13].
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